3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
33
Neoplasms
18
Colorectal Neoplasms
3
Skin Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Solid Tumor
1
Skin Diseases
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Cancer Metastatic
1
Biliary Tract Neoplasms
1
Advanced BRAF-mutant Cancers
1
Interventions
Paclitaxel
2
Carboplatin
2
zenocutuzumab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
entrectinib
1
cobimetinib
1
belinostat
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Mebendazole
1
Immunotherapy
1
HhAntag691
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Cisplatin
1
CP protocol
1
Biological Therapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Unknown Primary
×
Vemurafenib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts